

Better Use of Medicines Can Improve Health Outcomes and Reduce the Use of Costly Medical Care

Medicines play a central role in making our health care system more sustainable. The progress made against COVID-19 since the start of the pandemic illustrates how critical medicines are in overcoming our most pressing health care challenges. At the beginning of the pandemic, our hospital systems were overwhelmed, resources stretched, and death rates were growing at an alarming rate. Today, we have several vaccines available to help protect against the virus and therapeutics that can help reduce its consequences. Importantly, we also have the means to minimize the extraordinary burden that formerly threatened to overwhelm our health care system. In fact, since the introduction of novel COVID-19 vaccines, the U.S. vaccination program has been estimated to have saved 279,000 lives and averted up to 1.25 million hospitalizations.¹

That is because medicines have the ability not only to improve and save lives, but they can help avoid other, often costly, health care services, such as emergency room visits, hospital stays, surgeries and long-term care. Yet, despite the many health and economic benefits medicines provide, significant gaps in the use of medicines exist, and there are many diseases for which new medicines are desperately needed. To reduce these gaps, our strategy must include efforts to lessen the burden of diseases that disproportionately fall on communities of color and other underserved populations. Moving forward, medicines will continue to provide the best opportunity to meet critical unmet need, improve health and drive value and quality in our health care system.

The Economic Burden of Disease is Substantial

Six in ten Americans have one or more chronic conditions, and 42% have two or more.² The cost of treating these patients accounts for 90% of the nearly \$3.5 trillion spent on health care in the United States each year.^{3,4} The number of individuals with three or more chronic conditions is projected to nearly double by 2030, greatly increasing the economic burden of chronic disease.⁵ And while rare diseases by definition impact fewer than 200,000 patients, collectively, these diseases impose a significant economic burden on the United States. One study found nearly 400 rare diseases impacted 15.5 million Americans and cost the U.S. \$966 billion annually.⁶

Significant Gaps in Optimal Use of Medicines

Just 50% of medications for chronic disease are taken as prescribed.⁷ More than one-quarter of newly written prescriptions are never brought to the pharmacy to be filled, including those for common conditions such as high blood pressure, diabetes and high cholesterol.⁸ Additionally, failing to prescribe appropriate treatments is the most common prescribing quality problem.^{9,10} For example, more than one-third of patients newly diagnosed with heart failure do not receive recommended medicines as indicated within a month following diagnosis.¹¹ And despite the many novel diabetes medicines becoming available to patients over the past decade, the number of diabetes patients with their disease under control has declined and use of diabetes medicines has failed to keep pace with the growing number of high-risk patients with diabetes since 2010.¹²

Gaps in optimal use of medicines worsen outcomes for patients. Fewer than 1 in 5 U.S. adults with diabetes are meeting the recommended clinical goals with their current treatment regimen.¹³ Among patients with poorly controlled diabetes, Mexican and Black Americans are less likely to receive optimal treatment compared to non-Hispanic white Americans.¹⁴ The disparity in medicine use and disease management may help to explain why racially/ethnically diverse communities are disproportionately more likely to experience diabetes-related complications and death.¹⁵

Limited access to or restrictive coverage of medicines may also contribute to gaps in optimal medication use. The growing use of high deductibles and coinsurance for medicines presents affordability challenges for many patients. Individuals may also face other hurdles to filling prescriptions, such as prior authorization restrictions or step therapy requirements which require patients to try and fail other available therapies before being able to access prescribed treatments.^{16,17} Patients with chronic conditions are disproportionately affected by declining generosity of medication coverage, often leading patients to not adhere to prescribed treatment regimens or to abandon them altogether, resulting in poor outcomes.^{18,19,20,21,22}

Better Use of Medicines Can Improve Health Outcomes and Reduce Health Care Spending

Fortunately, where there are gaps, there are also tremendous opportunities to drive value in our health care system. In fact, better use of medicines could eliminate \$213 billion in U.S. health care costs annually, amounting to 8% of the nation's health care costs.²³

A large body of evidence demonstrates how better use of medicines can reduce other sources of health care spending across a broad range of chronic conditions. For example, spending \$1 more on medicines for adherent patients with congestive heart failure, high blood pressure, diabetes or high cholesterol can generate \$3 to \$10 in savings on emergency room visits and inpatient hospitalizations.²⁴ Savings due to improved use of medicines are also well documented in public programs.


The Congressional Budget Office credits Medicare policies that increase the use of medicines with savings on other Medicare costs.²⁵ As a result of seniors and people with disabilities gaining Medicare Part D prescription drug coverage, Medicare saved \$27 billion alone due to improved adherence to congestive heart failure medications.²⁶

Improving medication adherence among Medicare beneficiaries with various common chronic diseases could save billions in avoided hospital stays (see Figure 1).²⁷ Similarly, in Medicaid, research shows increased use of medicines among patients is associated with reductions in expenditures from avoided use of inpatient and outpatient services.²⁸ For example, among Medicaid patients with congestive heart failure, hypertension, high cholesterol, diabetes, asthma/chronic obstructive pulmonary disease, depression and schizophrenia/bipolar disorder, improving adherence could produce \$8 billion in savings annually.²⁹ Another study found if 60% of the children enrolled in Medicaid achieved high adherence to asthma treatment in just 14 states, Medicaid could achieve \$57.5 million in savings.³⁰ Patients with complex chronic diseases may also reduce their health care spending by exercising better adherence. For example, Medicare patients with Parkinson's disease, adults with Crohn's disease, children with cystic fibrosis and patients with multiple sclerosis and advanced melanoma have all been shown to achieve health care savings through improved use of medicines.^{31,32,33,34,35}

In addition to savings from avoided medical services, better use of medicines also improves health and overall quality of life, leading to reduced disability and fewer missed days of work. One study found the introduction of new treatments over the past decade increased worker productivity by 4.8 million workdays per year and resulted in \$221 billion in added annual wages.³⁶

Lowering cost-sharing at the pharmacy counter can also improve health outcomes and generate savings through improved adherence.³⁷ For example, passing through a portion of negotiated manufacturer rebates directly to Medicare beneficiaries taking diabetes medicine could lower patient out-of-pocket spending by \$367 per year, thereby improving adherence and preventing disease complications. As a result, this would save Medicare nearly \$1000 per senior per year and reduce total health care spending by approximately \$20 billion over ten years.³⁸ Similarly, in commercial health plans, if manufacturer rebates are shared with diabetes patients at the pharmacy counter, individuals could save a total of \$3.7 billion per year, or \$791 per person per year, and health plans could save \$305 million annually due to reductions in medical spending.³⁹

Outcomes With Improved Adherence



1 A Galvani, et al., Deaths and Hospitalizations Averted by Rapid U.S. Vaccination Rollout (Commonwealth Fund, July 2021).
 2 C Buttorff et al. *Multiple Chronic Conditions in the United States*. Rand Corporation, 2017.
 3 National Center for Chronic Disease Prevention and Health Promotion, *Health and Economic Costs of Chronic Diseases*.
 4 Centers for Medicare & Medicaid Services. *National health expenditures fact sheet*.
 5 Partnership for Chronic Disease. *What is the Impact of Chronic Disease on America?*
 6 The Everlylife Foundation, *The National Economic Burden of Chronic Disease Study*. The Lewin Group, February 2021.
 7 M Viswanathan et al. *Interventions to Improve Adherence to Self-Administered Medications for Chronic Diseases in the United States: A Systemic Review*. Annals of Internal Medicine, December 2012.
 8 MA Fischer et al. *Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions*. Journal of General Internal Medicine. 25 no. 4 (2010): 284-90.
 9 DP Goldman, et al. *RAND Health. US Health Care: Facts about Cost, Access, and Quality*. Santa Monica, CA: RAND Corporation; 2005. Cited by: Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. *Ann Intern Med*. 2004;14(9):714-720.
 10 TD Sorensen et al. *Seeing the Forest Through the Trees: Improving Adherence Alone Will Not Optimize Medication Use*. Journal of Managed Care & Specialty Pharmacy. Vol. 22, No. 5. May 2016.
 11 C Deschaseaux et al., *Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis*. J Manag Care Spec Pharm, 2016 May;22(5):561-57
 12 Fang M, et al. *Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018*. N Engl J Med 2021; 384:2219-2228.
 13 Wang L, et al. *Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999–2018*. JAMA. Published online June 25, 2021.
 14 M Fang, et al. *Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018*. NEJM;2021, 384:2219-2228
 15 Tan T, et al. *Association between race/ethnicity and the risk of amputation of lower extremities among medicare beneficiaries with diabetic foot ulcers and diabetic foot infections*. BMJ Open Diabetes Research and Care 2020;8:e001328.
 16 IMS Institute for Healthcare Informatics. *Emergency and Impact of Pharmacy Deductibles: Implications for Patients in Commercial Health Plans*. September 2015.
 17 Kaiser Family Health Foundation. *2019 Employer Health benefits Survey*. September 2019.
 18 MT Eaddy, et al. *How Patient Cost-Sharing Trends Affect Adherence and Outcomes*. Pharmacy & Therapeutics. 2012;37(1):45-55
 19 JA Doshi, et al. *High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients with Newly Diagnosed Chronic Myeloid Leukemia*. American Journal of Managed Care. 2016;22(4 Suppl):S78-S86.
 20 IQVIA. *Patient affordability part one: the implications of changing benefit designs and high cost-sharing*. May 18, 2018.
 21 IQVIA. *Patient affordability part two: implications for patient behavior and therapy consumption*.
 22 IMS Institute for Healthcare Informatics. *Emergence and impact of pharmacy deductibles: implications for patients in commercial health plans*. <https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/emergence-and-impact-of-pharmacy-deductibles.pdf>
 23 IMS Institute for Healthcare Informatics. *Avoidable costs in US healthcare: the \$200 billion opportunity from using medicines more responsibly*. June 2013.
 24 MC Roebuck et al. *"Medication Adherence Leads To Lower Health Care Use And Costs Despite Increased Drug Spending."* Health Affairs 30 no. 1 (2011): 91-9.
 25 CBO. *Offsetting Effects of Prescription Drug Use on Medicare's Spending for Medical Services*. November 2012.
 26 TM Dall et al. *The Economic Impact of Medicare Part D Coverage on Congestive Heart Failure*. AJMC, 2013;19:S97-S100.
 27 Lloyd, Jennifer T, et al. *"How much does medication nonadherence cost the medicare fee-for-service program?"* Medical care 57.3 (2019): 218-224.
 28 MC Roebuck et al. *Medical Cost Offsets from Prescription Drug Use in Medicaid*. Health Aff September 2015 vol. 34no. 9 1586-1593.
 29 MC Roebuck, et al. *"Impact of Medication Adherence on Health Services Utilization in Medicaid."* Medical care 56.3 (2018): 266-273.
 30 G Rust, et al. *Potential Savings from Increasing Adherence to Inhaled Corticosteroid Therapy in Medicaid-Enrolled Children*. AJMC 2015 March 21(3):173-180.
 31 YJ Wei, et al. *Antiparkinson Drug Adherence and Its Association with Health Care Utilization and Economic Outcomes in a Medicare Part D Population*. Value in Health 2014 17(2), 196-204.
 32 BG Feagan, et al. *Healthcare Costs for Crohn's Disease Patients Treated with Infliximab: A propensity Weighted Comparison of the Effects of Treatment Adherence*. J Med Econ. 2014;17(12):872-80.
 33 AL Quittner et al., *Pulmonary Medication Adherence and Health-Care Use in Cystic Fibrosis*. CHEST Journal 2014, 146(1), 142-151.
 34 NJ Boster, et al. *Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data*. Pharmacoecoen Open. 2018;2(1):31-41.
 35 K Gupte-Singh, et al. *Proceedings of the 22nd Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research*; 2017 May.
 36 Chen AJ, et al., *"Productivity benefits of medical care: evidence from US-based randomized clinical trials"*. Value in Health. 2018 Aug;21(8):905-910.
 37 Cong, M, et al. (2021). *Association of Co-Pay Elimination with Medication Adherence and Total Cost*, AJMC, (Vol. 27, pp. 249-254).
 38 Su W, Dall T, IHS Markit. *Passing a portion of negotiated rebates through to seniors with diabetes can improve adherence and generate savings in Medicare*. May 2018.
 39 Partnership for Fighting Chronic Disease, *Sharing Rebates on Diabetes Medicines Could Save People With Diabetes \$3.7 Billion A Year*. (2019)